De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Ardelyx Beheer

Beheer criteriumcontroles 3/4

De CEO Ardelyx's is Mike Raab, benoemd in Mar2009, heeft een ambtstermijn van 15.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 4.12M, bestaande uit 17% salaris en 83% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.53% van de aandelen van het bedrijf, ter waarde $ 8.56M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.3 jaar en 9 jaar.

Belangrijke informatie

Mike Raab

Algemeen directeur

US$4.1m

Totale compensatie

Percentage CEO-salaris	17.0%
Dienstverband CEO	15.6yrs
Eigendom CEO	0.5%
Management gemiddelde ambtstermijn	4.3yrs
Gemiddelde ambtstermijn bestuur	9yrs

Recente managementupdates

Recent updates

Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?

Aug 25

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Aug 07

Ardelyx Faces Rising Challenges Despite Revenue Growth

Aug 05

Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 04

Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook

Jul 13

Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge

Jul 05

Ardelyx: Strong Execution, Fairly Valued

May 10

Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 04

Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)

May 03

Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Apr 17

Ardelyx Shrugs Off 'Mixed' Q4 Earnings

Mar 13

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 24

Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance

Feb 20

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Aug 03

Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

Jul 31

Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now

Apr 17

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Mar 30

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Dec 14

What To Expect For Ardelyx In The Coming Month

Oct 18

Ardelyx: Potential For Growth, But Must Strengthen Its Financial Position

Oct 04

Ardelyx secures $20M financial deal with HealthCare Royalty on tenapanor potential sale

Jun 30

Analyse CEO-vergoeding

Hoe is Mike Raab's beloning veranderd ten opzichte van Ardelyx's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$65m
Mar 31 2024	n/a	n/a	-US$66m
Dec 31 2023	US$4m	US$700k	-US$66m
Sep 30 2023	n/a	n/a	-US$27m
Jun 30 2023	n/a	n/a	-US$56m
Mar 31 2023	n/a	n/a	-US$66m
Dec 31 2022	US$2m	US$650k	-US$67m
Sep 30 2022	n/a	n/a	-US$114m
Jun 30 2022	n/a	n/a	-US$135m
Mar 31 2022	n/a	n/a	-US$153m
Dec 31 2021	US$4m	US$650k	-US$158m
Sep 30 2021	n/a	n/a	-US$151m
Jun 30 2021	n/a	n/a	-US$125m
Mar 31 2021	n/a	n/a	-US$105m
Dec 31 2020	US$4m	US$633k	-US$94m
Sep 30 2020	n/a	n/a	-US$85m
Jun 30 2020	n/a	n/a	-US$91m
Mar 31 2020	n/a	n/a	-US$91m
Dec 31 2019	US$2m	US$595k	-US$95m
Sep 30 2019	n/a	n/a	-US$103m
Jun 30 2019	n/a	n/a	-US$104m
Mar 31 2019	n/a	n/a	-US$100m
Dec 31 2018	US$4m	US$575k	-US$91m
Sep 30 2018	n/a	n/a	-US$53m
Jun 30 2018	n/a	n/a	-US$50m
Mar 31 2018	n/a	n/a	-US$53m
Dec 31 2017	US$5m	US$555k	-US$64m

Compensatie versus markt: De totale vergoeding ($USD 4.12M ) Mike } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).

Compensatie versus inkomsten: De vergoeding van Mike is gestegen terwijl het bedrijf verliesgevend is.

CEO

Mike Raab (59 yo)

15.6yrs

Tenure

US$4,118,144

Compensatie

Mr. Michael G. Raab, also known as Mike, has been the Chief Executive Officer and President of Ardelyx, Inc. since March 2009. He is a Director of Tempest Therapeutics Inc. since May 2019 and its Chairman...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Raab	President	15.6yrs	US$4.12m	0.53% $ 8.5m
Elizabeth Grammer	Chief Legal & Administrative Officer and Secretary	10.4yrs	US$1.63m	0.082% $ 1.3m
Laura Williams	Chief Medical Officer	3.9yrs	US$1.63m	0.13% $ 2.1m
Justin Renz	Chief Financial & Operations Officer	4.3yrs	US$1.73m	0.13% $ 2.0m
Robert Felsch	Senior VP of Finance & Chief Accounting Officer	2.6yrs	geen gegevens	0.039% $ 624.4k
Caitlin Lowie	Vice President of Corporate Communications & Investor Relations	no data	geen gegevens	geen gegevens
Mike Kelliher	Executive Vice President of Corporate Development & Strategy	less than a year	geen gegevens	geen gegevens
Charon Spencer	Chief Human Resources Officer	1.8yrs	geen gegevens	geen gegevens
David Rosenbaum	Chief Development Officer	9.8yrs	US$1.63m	0.23% $ 3.6m
Robert Blanks	Chief Regulatory Affairs & Quality Assurance Officer	no data	US$1.70m	0.14% $ 2.2m
Susan Rodriguez	Advisor	4.4yrs	US$1.04m	0.19% $ 3.1m
Kimia Keshtbod	Manager of Corporate Communications & Investor Relations	no data	geen gegevens	geen gegevens

4.3yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ARDX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Raab	President	15.6yrs	US$4.12m	0.53% $ 8.5m
David Mott	Independent Chairman of the Board	15.6yrs	US$249.90k	0.51% $ 8.2m
William C. Bertrand	Independent Director	9yrs	US$214.90k	0.098% $ 1.6m
Richard Rodgers	Independent Director	10.6yrs	US$222.40k	0.11% $ 1.7m
Robert Bazemore	Independent Director	8.3yrs	US$202.40k	geen gegevens
Onaiza Cadoret-Manier	Independent Director	4.6yrs	US$199.90k	0.047% $ 751.3k
Muna Bhanji	Independent Director	3.6yrs	US$202.40k	0.041% $ 653.3k

9.0yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ARDX wordt beschouwd als ervaren (gemiddelde ambtstermijn 9 jaar).

Ardelyx Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Ardelyx, Inc. Appoints Eric Foster as Chief Commercial Officer

Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer

President recently sold US$246k worth of stock

Insider recently sold US$782k worth of stock

Insider notifies of intention to sell stock

President notifies of intention to sell stock

Recent updates

Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?

Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action

Ardelyx, Inc. Appoints Eric Foster as Chief Commercial Officer

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Ardelyx Faces Rising Challenges Despite Revenue Growth

Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Ardelyx, Inc. Announces Publication of Two Plain Language Summaries from XPHOZAH®? (tenapanor) Clinical Trials in Current Medical Research and Opinion

Ardelyx, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook

Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge

Ardelyx, Inc.(NasdaqGM:ARDX) dropped from Russell Small Cap Comp Value Index

Ardelyx, Inc. Chooses Not to File for TDAPA to Preserve Patient Access to XPHOZAH

Ardelyx, Inc. Announces Rodriguez Would Resign as Chief Commercial Officer

President recently sold US$246k worth of stock

Insider recently sold US$782k worth of stock

Ardelyx: Strong Execution, Fairly Valued

Consensus revenue estimates increase by 18%

Insider notifies of intention to sell stock

Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date pushed back to 2026

Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)

President notifies of intention to sell stock

Ardelyx, Inc., Annual General Meeting, Jun 14, 2024

Ardelyx, Inc. to Report Q1, 2024 Results on May 02, 2024

Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Price target increased by 7.1% to US$13.39

Ardelyx, Inc. Announces the Appointment of Mike Kelliher as Executive Vice President, Corporate Development and Strategy

Insider notifies of intention to sell stock

Ardelyx Shrugs Off 'Mixed' Q4 Earnings

Ardelyx, Inc. announced that it has received $50 million in funding

Consensus EPS estimates fall by 95%, revenue upgraded

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS misses analyst expectations

Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance

Ardelyx, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Ardelyx's XPHOZAH Still An Afterthought To The Pros

Consensus estimates of losses per share improve by 10%

Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement

Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price

Key Executive notifies of intention to sell stock

Price target increased by 9.5% to US$9.94

Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt

Insider notifies of intention to sell stock

Ardelyx Announces Departure of Geoffrey Block as Board Member

Ardelyx, Inc. Announces XPHOZAH(R) (tenapanor) Now Available in the United States

Consensus revenue estimates increase by 16%

Ardelyx Shares Positive Data from Studies of Xphozah®? (Tenapanor) At Asn Kidney Week 2023

Price target increased by 10% to US$9.36

Ardelyx, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Ardelyx, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Insufficient new directors

Ardelyx, Inc. Shares Positive Data on Symptom Response During Treatment with IBSRELA®? (tenapanor) for IBS-C and Hosts IBS-C Product Theater at ACG 2023

Ardelyx, Inc. Announces FDA Approval of XPHOZAH (tenapanor), a First-In-Class Phosphate Absorption Inhibitor

Ardelyx, Inc. Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

Consensus revenue estimates increase by 17%

New major risk - Shareholder dilution

Price target increased by 7.1% to US$7.58

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

Ardelyx, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Insider notifies of intention to sell stock

Forecast breakeven date pushed back to 2025

Ardelyx, Inc. Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH(R)

Consensus EPS estimates fall by 47%, revenue upgraded

Price target increased by 7.6% to US$7.08

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind